Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer
McGahan L
Record ID 32017000164
English
Authors' recommendations:
Palbociclib is a first-in-class CDK4/6 inhibitor for use in combination with fulvestrant as second-line treatment for HR-positive, HER2-negative advanced or MBC with disease progression during or following ET. While palbociclib increased median PFS by 4.9 months, this endpoint is not currently supported by OS data or clinically important differences in QoL. Physician and patient preference contribute to palbociclib's place in therapy due to the lack of OS data and head-to-head comparisons of first-line versus subsequent-line use. While the Rb protein is the only reliable indicator for palbociclib activity, further indicators and biomarkers may be of benefit for future use.
Details
Project Status:
Completed
URL for project:
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published:
2017
URL for published report:
http://eprints.hta.lbg.ac.at/1114/1/DSD_HSO_Nr.64.pdf
URL for additional information:
http://eprints.hta.lbg.ac.at/1114/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Breast Neoplasms
- Estradiol
- Fulvestrant
- Piperazines
- Pyridines
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.